Annual Cash & Cash Equivalents
$944.07 M
-$371.72 M-28.25%
December 31, 2023
Summary
- As of February 8, 2025, DNA annual cash & cash equivalents is $944.07 million, with the most recent change of -$371.72 million (-28.25%) on December 31, 2023.
- During the last 3 years, DNA annual cash & cash equivalents has risen by +$563.27 million (+147.92%).
- DNA annual cash & cash equivalents is now -39.09% below its all-time high of $1.55 billion, reached on December 31, 2021.
Performance
DNA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$616.21 M
-$114.15 M-15.63%
September 30, 2024
Summary
- As of February 8, 2025, DNA quarterly cash and cash equivalents is $616.21 million, with the most recent change of -$114.15 million (-15.63%) on September 30, 2024.
- Over the past year, DNA quarterly cash and cash equivalents has dropped by -$327.86 million (-34.73%).
- DNA quarterly cash and cash equivalents is now -64.57% below its all-time high of $1.74 billion, reached on September 30, 2021.
Performance
DNA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
DNA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -28.3% | -34.7% |
| 3 y3 years | +147.9% | -34.7% |
| 5 y5 years | - | - |
DNA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -39.1% | at low | -60.2% | at low |
| 5 y | 5-year | -39.1% | +147.9% | -64.6% | +61.8% |
| alltime | all time | -39.1% | +147.9% | -64.6% | +61.8% |
Ginkgo Bioworks Holdings Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $616.21 M(-15.6%) |
| Jun 2024 | - | $730.37 M(-13.1%) |
| Mar 2024 | - | $840.44 M(-11.0%) |
| Dec 2023 | $944.07 M(-28.3%) | $944.07 M(-10.0%) |
| Sep 2023 | - | $1.05 B(-5.1%) |
| Jun 2023 | - | $1.11 B(-8.3%) |
| Mar 2023 | - | $1.21 B(-8.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $1.32 B(-15.1%) | $1.32 B(+1.0%) |
| Sep 2022 | - | $1.30 B(-5.4%) |
| Jun 2022 | - | $1.38 B(-7.8%) |
| Mar 2022 | - | $1.49 B(-3.7%) |
| Dec 2021 | $1.55 B(+307.0%) | $1.55 B(-10.9%) |
| Sep 2021 | - | $1.74 B(+356.7%) |
| Dec 2020 | $380.80 M | $380.80 M |
FAQ
- What is Ginkgo Bioworks Holdings annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Ginkgo Bioworks Holdings?
- What is Ginkgo Bioworks Holdings annual cash & cash equivalents year-on-year change?
- What is Ginkgo Bioworks Holdings quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Ginkgo Bioworks Holdings?
- What is Ginkgo Bioworks Holdings quarterly cash and cash equivalents year-on-year change?
What is Ginkgo Bioworks Holdings annual cash & cash equivalents?
The current annual cash & cash equivalents of DNA is $944.07 M
What is the all time high annual cash & cash equivalents for Ginkgo Bioworks Holdings?
Ginkgo Bioworks Holdings all-time high annual cash & cash equivalents is $1.55 B
What is Ginkgo Bioworks Holdings annual cash & cash equivalents year-on-year change?
Over the past year, DNA annual cash & cash equivalents has changed by -$371.72 M (-28.25%)
What is Ginkgo Bioworks Holdings quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of DNA is $616.21 M
What is the all time high quarterly cash and cash equivalents for Ginkgo Bioworks Holdings?
Ginkgo Bioworks Holdings all-time high quarterly cash and cash equivalents is $1.74 B
What is Ginkgo Bioworks Holdings quarterly cash and cash equivalents year-on-year change?
Over the past year, DNA quarterly cash and cash equivalents has changed by -$327.86 M (-34.73%)